vs
ADAMAS TRUST, INC.（ADAM）与Cytek Biosciences, Inc.（CTKB）财务数据对比。点击上方公司名可切换其他公司
Cytek Biosciences, Inc.的季度营收约是ADAMAS TRUST, INC.的1.4倍（$62.1M vs $43.2M），ADAMAS TRUST, INC.净利率更高（124.0% vs -70.9%，领先194.9%），ADAMAS TRUST, INC.同比增速更快（61.6% vs 8.1%），ADAMAS TRUST, INC.自由现金流更多（$125.9M vs $-1.8M），过去两年ADAMAS TRUST, INC.的营收复合增速更高（55.5% vs 17.7%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
ADAM vs CTKB — 直观对比
营收规模更大
CTKB
是对方的1.4倍
$43.2M
营收增速更快
ADAM
高出53.5%
8.1%
净利率更高
ADAM
高出194.9%
-70.9%
自由现金流更多
ADAM
多$127.7M
$-1.8M
两年增速更快
ADAM
近两年复合增速
17.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.2M | $62.1M |
| 净利润 | $53.5M | $-44.1M |
| 毛利率 | — | 52.9% |
| 营业利润率 | — | -9.0% |
| 净利率 | 124.0% | -70.9% |
| 营收同比 | 61.6% | 8.1% |
| 净利润同比 | 270.5% | -557.1% |
| 每股收益（稀释后） | $0.45 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADAMCTKB
| Q4 25 | $43.2M | $62.1M | ||
| Q3 25 | $36.6M | $52.3M | ||
| Q2 25 | $36.4M | $45.6M | ||
| Q1 25 | $33.1M | $41.5M | ||
| Q4 24 | $26.7M | $57.5M | ||
| Q3 24 | $20.2M | $51.5M | ||
| Q2 24 | $19.0M | $46.6M | ||
| Q1 24 | $17.9M | $44.9M |
净利润ADAMCTKB
| Q4 25 | $53.5M | $-44.1M | ||
| Q3 25 | $44.8M | $-5.5M | ||
| Q2 25 | $8.5M | $-5.6M | ||
| Q1 25 | $42.2M | $-11.4M | ||
| Q4 24 | $-31.4M | $9.6M | ||
| Q3 24 | $42.8M | $941.0K | ||
| Q2 24 | $-15.6M | $-10.4M | ||
| Q1 24 | $-57.9M | $-6.2M |
毛利率ADAMCTKB
| Q4 25 | — | 52.9% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 58.5% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 54.6% | ||
| Q1 24 | — | 51.3% |
营业利润率ADAMCTKB
| Q4 25 | — | -9.0% | ||
| Q3 25 | — | -17.6% | ||
| Q2 25 | 11.7% | -23.3% | ||
| Q1 25 | — | -36.1% | ||
| Q4 24 | -119.0% | 5.2% | ||
| Q3 24 | — | -8.2% | ||
| Q2 24 | -124.7% | -18.3% | ||
| Q1 24 | -448.8% | -23.9% |
净利率ADAMCTKB
| Q4 25 | 124.0% | -70.9% | ||
| Q3 25 | 122.5% | -10.5% | ||
| Q2 25 | 23.4% | -12.2% | ||
| Q1 25 | 127.4% | -27.5% | ||
| Q4 24 | -117.5% | 16.8% | ||
| Q3 24 | 211.7% | 1.8% | ||
| Q2 24 | -81.9% | -22.4% | ||
| Q1 24 | -324.1% | -13.8% |
每股收益（稀释后）ADAMCTKB
| Q4 25 | $0.45 | — | ||
| Q3 25 | $0.36 | — | ||
| Q2 25 | $-0.04 | — | ||
| Q1 25 | $0.33 | — | ||
| Q4 24 | $-0.46 | — | ||
| Q3 24 | $0.36 | — | ||
| Q2 24 | $-0.29 | — | ||
| Q1 24 | $-0.75 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $210.3M | $90.9M |
| 总债务越低越好 | $735.8M | — |
| 股东权益账面价值 | $1.4B | $341.7M |
| 总资产 | $12.6B | $461.5M |
| 负债/权益比越低杠杆越低 | 0.52× | — |
8季度趋势，按日历期对齐
现金及短期投资ADAMCTKB
| Q4 25 | $210.3M | $90.9M | ||
| Q3 25 | $185.3M | $93.3M | ||
| Q2 25 | $160.4M | $75.5M | ||
| Q1 25 | $177.1M | $95.3M | ||
| Q4 24 | $167.4M | $98.7M | ||
| Q3 24 | $195.1M | $162.3M | ||
| Q2 24 | $235.5M | $177.9M | ||
| Q1 24 | $226.9M | $168.8M |
总债务ADAMCTKB
| Q4 25 | $735.8M | — | ||
| Q3 25 | $766.6M | — | ||
| Q2 25 | $653.0M | — | ||
| Q1 25 | $654.4M | — | ||
| Q4 24 | $573.2M | — | ||
| Q3 24 | $699.4M | — | ||
| Q2 24 | $800.7M | — | ||
| Q1 24 | $1.0B | — |
股东权益ADAMCTKB
| Q4 25 | $1.4B | $341.7M | ||
| Q3 25 | $1.4B | $378.6M | ||
| Q2 25 | $1.4B | $377.6M | ||
| Q1 25 | $1.4B | $379.6M | ||
| Q4 24 | $1.4B | $395.7M | ||
| Q3 24 | $1.4B | $385.5M | ||
| Q2 24 | $1.4B | $389.1M | ||
| Q1 24 | $1.5B | $392.6M |
总资产ADAMCTKB
| Q4 25 | $12.6B | $461.5M | ||
| Q3 25 | $12.4B | $494.9M | ||
| Q2 25 | $10.6B | $493.3M | ||
| Q1 25 | $10.0B | $482.6M | ||
| Q4 24 | $9.2B | $499.5M | ||
| Q3 24 | $8.9B | $491.2M | ||
| Q2 24 | $8.2B | $483.7M | ||
| Q1 24 | $7.4B | $492.1M |
负债/权益比ADAMCTKB
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.55× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.56× | — | ||
| Q1 24 | 0.67× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.0M | $-771.0K |
| 自由现金流经营现金流 - 资本支出 | $125.9M | $-1.8M |
| 自由现金流率自由现金流/营收 | 291.6% | -2.9% |
| 资本支出强度资本支出/营收 | 18.9% | 1.6% |
| 现金转化率经营现金流/净利润 | 2.50× | — |
| 过去12个月自由现金流最近4个季度 | — | $-8.8M |
8季度趋势，按日历期对齐
经营现金流ADAMCTKB
| Q4 25 | $134.0M | $-771.0K | ||
| Q3 25 | $6.9M | $-3.9M | ||
| Q2 25 | $39.2M | $108.0K | ||
| Q1 25 | $25.8M | $-125.0K | ||
| Q4 24 | $14.1M | $2.0M | ||
| Q3 24 | $-922.0K | $13.2M | ||
| Q2 24 | $-993.0K | $6.2M | ||
| Q1 24 | $-13.1M | $4.0M |
自由现金流ADAMCTKB
| Q4 25 | $125.9M | $-1.8M | ||
| Q3 25 | — | $-4.6M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-974.0K | ||
| Q4 24 | $-10.6M | $1.1M | ||
| Q3 24 | $-8.6M | $12.2M | ||
| Q2 24 | $-8.6M | $5.2M | ||
| Q1 24 | $-19.1M | $3.4M |
自由现金流率ADAMCTKB
| Q4 25 | 291.6% | -2.9% | ||
| Q3 25 | — | -8.7% | ||
| Q2 25 | — | -3.2% | ||
| Q1 25 | — | -2.3% | ||
| Q4 24 | -39.6% | 1.9% | ||
| Q3 24 | -42.3% | 23.7% | ||
| Q2 24 | -44.9% | 11.0% | ||
| Q1 24 | -107.0% | 7.6% |
资本支出强度ADAMCTKB
| Q4 25 | 18.9% | 1.6% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | 92.3% | 1.6% | ||
| Q3 24 | 37.7% | 2.0% | ||
| Q2 24 | 39.7% | 2.3% | ||
| Q1 24 | 33.5% | 1.3% |
现金转化率ADAMCTKB
| Q4 25 | 2.50× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 4.59× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | -0.02× | 14.05× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADAM
| Other | $19.6M | 45% |
| Constructive Loans LLC | $14.4M | 33% |
| Multifamily | $9.1M | 21% |
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
